Open AccessRecapitulating the Pharmacological Interactions of Cetuximab with Sunitinib and Cisplatin in Head and Neck Carcinoma Cells in vitro
Author(s) -
Maria Dib,
Nathanil Justian,
Christian Scheffold,
ChiaJung Busch,
Martin Burchardt,
Pedro Caetano-Pinto
Publication year - 2022
Publication title -
pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.51
H-Index - 59
eISSN - 1423-0313
pISSN - 0031-7012
DOI - 10.1159/000527082
Subject(s) - cetuximab , cisplatin , sunitinib , cancer research , head and neck cancer , head and neck squamous cell carcinoma , cancer cell , pharmacology , efflux , medicine , cancer , chemistry , colorectal cancer , chemotherapy , biochemistry
Cisplatin is extensively used in the treatment of head and neck carcinomas. Cetuximab combination therapy is employed in recurrent and metastatic settings. Sunitinib showed positive results in the treatment of head and neck carcinomas, both as monotherapy or in combination with cetuximab. Nonetheless, the mechanism governing these pharmacological interactions is largely unresolved. This study investigates the impact of cetuximab on the cytotoxicity of cisplatin and sunitinib using cells representative of head and neck carcinoma and the oral epithelium.